What is hurting Indian pharma more—misinformation or price control?
The industry body is lashing out at the regulator for stifling a growing industry. But the members say the drug companies are doing just fine
In hushed tones, senior executives of some of the largest pharmaceutical companies say that they want to work with the regulator and abide by the law but Dilip G Shah has taken the conflict very personally
The public posturing of the IPA, which is in sharp contrast to its own report, shows the extent of the misinformation being floated
The industry agrees that in the last three years, price regulation has affected them only marginally, not nearly enough to reverse the growth
To look into the matter, the DoP has set up a committee, whose objective is to ensure enhanced access to drugs and a streamlined price control mechanism
On 13 April, a day before the Easter weekend, many drug manufacturers went on their breaks feeling a little agitated but mostly helpless. It was the day, the spokesperson of the Indian Pharmaceutical Alliance (IPA), representing its (invite only) members—over 20 large companies including Sun Pharma, Dr Reddy’s, Lupin and Cipla—went public with his anger.
Dilip G Shah referred to the pricing policy roll-out as “arbitrary”, and compliance to guidelines “difficult”. Shah claimed these two factors were adding to the “woes” of the drug industry.
Sign up to read this story for free right away
Stories on The Ken are available only for its subscribers. This story is shared with you for free, just sign up to get instant access.
Get full access to all stories on The Ken. Rs. 2,750/year or Rs. 900/quarter
Dear subscriber - a lot of hard work goes into the journalism we put out. While sharing snippets or limited screenshots is okay, please avoid printing and sharing our entire articles as PDFs. Our plans are very affordable - please ask your friends to subscribe.